PMID- 24790245
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20140505
LR  - 20211021
IS  - 0011-393X (Print)
IS  - 0011-393X (Linking)
VI  - 66
IP  - 5
DP  - 2005 Sep
TI  - Therapy for treatment-refractory chronic hepatitis C virus genotype 1b infection: 
      A retrospective analysis.
PG  - 451-62
LID - 10.1016/j.curtheres.2005.10.002 [doi]
AB  - BACKGROUND: The most effective current therapy for hepatitis C virus (HCV) 
      infection is the combination of pegylated interferon (peg-IFN) plus ribavirin 
      (RBV). OBJECTIVE: The aim of this retrospective analysis was to determine the 
      rateof response to this therapy, and the factors affecting outcome, in patients 
      with treatment-refractory chronic HCV genotype l b. METHODS: The records of 
      patients with chronic HCV infection and HCV geno-type1b who failed (nonresponse 
      or relapse) previous treatment with standard interferon (IFN) + RSV were 
      retrospectively analyzed for demographic data, virologic load, liver histology, 
      biochemistry, treatment-related adverse effects (AEs), and the effects of dose 
      reduction during treatment with peg-IFN + RBV for 48 weeks. Early virologic 
      response (EVR) was defined as >/=2-log (copies/mL) decrease from baseline in serum 
      HCV RNA concentration or the absence of detectable serum HCV RNA at treatment 
      week 12. End-of-treatment response (ETR) was defined as the absence of detectable 
      serum HCV RNA at treatment week 48. Sustained virologic response (SVR) was 
      defined as the absence of detectable serum HCV RNA 24 weeks after treatment was 
      discontinued. Factors affecting treatment outcome were determined using 
      correlation analyses. RESULTS: Data from the files of 17 patients (12 men, 5 
      women; mean [SD] age, 48 [2] years) were analyzed. EVR was achieved in 7 
      patients; however, viral breakthrough occurred in 2 of these patients during the 
      treatment period, and 5 of these patients discontinued treatment because of 
      severe treatment-related AEs (depression [1 patient] and neutropenia [4]). Seven 
      patients achieved ETR, but HCV infection relapsed during the follow-up period. 
      Three (18%) patients achieved SVR. Data concerning previous patterns of response 
      to IFN + RBV therapy were available in 10 patients. Of these, 3 of 6 patients who 
      had experienced relapse with the previous treatment achieved SVR with peg-IFN + 
      RBV; neither of the 2 patients with nonresponse to the previous treatment 
      achieved SVR. Major determinants of failure to reach SVR in these patients 
      included previous nonresponder pattern, noncompliance with the therapy, and 
      advanced-stage liver fibrosis. Tolerability was similar to that with the previous 
      treatment. CONCLUSIONS: In this study in patients with chronic HCV genotype lb 
      infectionand a history of relapse or nonresponse to standard IFN + RSV treatment, 
      treatment with peg-IFN + RBV achieved an SVR rate of 18%. Further research is 
      needed to determine the role of peg-IFN + RBV in the re-treatment of HCV 
      infection.
FAU - Cindoruk, Mehmet
AU  - Cindoruk M
AD  - Department of Gastroenterology, Faculty of Medicine, Gazi University, 
      Ankara,Turkey.
FAU - Karakan, Tarkan
AU  - Karakan T
AD  - Department of Gastroenterology, Faculty of Medicine, Gazi University, 
      Ankara,Turkey.
FAU - Unal, Selahattin
AU  - Unal S
AD  - Department of Gastroenterology, Faculty of Medicine, Gazi University, 
      Ankara,Turkey.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Curr Ther Res Clin Exp
JT  - Current therapeutic research, clinical and experimental
JID - 0372621
PMC - PMC4003808
OTO - NOTNLM
OT  - hepatitis C
OT  - nonresponders
OT  - pegylated interferon
OT  - retrospective
OT  - ribavirin combination
OT  - treatment
OT  - treatment failure
EDAT- 2005/09/01 00:00
MHDA- 2005/09/01 00:01
PMCR- 2005/09/01
CRDT- 2014/05/03 06:00
PHST- 2005/07/13 00:00 [accepted]
PHST- 2014/05/03 06:00 [entrez]
PHST- 2005/09/01 00:00 [pubmed]
PHST- 2005/09/01 00:01 [medline]
PHST- 2005/09/01 00:00 [pmc-release]
AID - S0011-393X(05)00094-9 [pii]
AID - 10.1016/j.curtheres.2005.10.002 [doi]
PST - ppublish
SO  - Curr Ther Res Clin Exp. 2005 Sep;66(5):451-62. doi: 
      10.1016/j.curtheres.2005.10.002.